{"doi":"10.1200/edbk_432520","title":"Big Decisions on Small Cell Lung Cancer: A Focus on Clinical Care Updates and Patient Perspectives","abstract":"<jats:p> Small cell lung cancer (SCLC) is an uncommon, aggressive high-grade neuroendocrine carcinoma, associated with tobacco use. It is a highly chemosensitive disease that initially responds quickly to systemic therapy, although patients with SCLC tend to develop relapse. Although the landscape of SCLC treatment has remained stagnant for many decades, the field has seen notable advances in the past few years, including the use of immunotherapy, the development of further lines of systemic therapy, the refinement of thoracic and intracranial radiotherapy, and—most recently—the promise of more targeted therapies. Patients with SCLC also must face unique psychosocial burdens in their experience with their cancer, distinct from patients with other lung cancer. In this article, we review the latest literature and future directions in the management and investigation of SCLC, as well as the critical decisions that providers and patients must navigate in the current landscape. We also present the perspectives of several patients with SCLC in conjunction with this summary, to spotlight their individual journeys in the context of this challenging disease. </jats:p>","journal":"American Society of Clinical Oncology Educational Book","year":2024,"id":603418,"datarank":0.29188652235829704,"base_score":1.9459101490553132,"endowment":1.9459101490553132,"self_citation_contribution":0.29188652235829704,"citation_network_contribution":0.0,"self_endowment_contribution":0.29188652235829704,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":6,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":74869,"name":"Anne C. Chiang","orcid":"0000-0002-2111-4694","position":1,"is_corresponding":false},{"id":1060761,"name":"Xiao Wang","orcid":"0000-0002-9647-8847","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Big Decisions on Small Cell Lung Cancer: A Focus on Clinical Care Updates and Patient Perspectives","abstract":"<jats:p> Small cell lung cancer (SCLC) is an uncommon, aggressive high-grade neuroendocrine carcinoma, associated with tobacco use. It is a highly chemosensitive disease that initially responds quickly to systemic therapy, although patients with SCLC tend to develop relapse. Although the landscape of SCLC treatment has remained stagnant for many decades, the field has seen notable advances in the past few years, including the use of immunotherapy, the development of further lines of systemic therapy, the refinement of thoracic and intracranial radiotherapy, and—most recently—the promise of more targeted therapies. Patients with SCLC also must face unique psychosocial burdens in their experience with their cancer, distinct from patients with other lung cancer. In this article, we review the latest literature and future directions in the management and investigation of SCLC, as well as the critical decisions that providers and patients must navigate in the current landscape. We also present the perspectives of several patients with SCLC in conjunction with this summary, to spotlight their individual journeys in the context of this challenging disease. </jats:p>","is_dataset_classified":null,"base_score":1.791759469228055,"endowment":1.791759469228055,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"38830134","pmcid":null,"openalex_id":"https://openalex.org/W4399281438","authors":[],"funders":[],"total_grants":0,"fwci":1.1397,"citation_percentile":0.80634259,"influential_citations":0,"citation_trend":[{"year":2024,"count":1},{"year":2025,"count":2},{"year":2026,"count":2}],"oa_status":"closed","license":null,"oa_locations":[{"url":"https://ascopubs.org/doi/pdfdirect/10.1200/EDBK_432520","host_type":"publisher"},{"url":"https://doi.org/10.1200/edbk_432520","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/38830134","host_type":"repository"}],"fields_of_study":["Lung Cancer Research Studies","Neuroendocrine Tumor Research Advances","Lung Cancer Treatments and Mutations","Humans","Small Cell Lung Carcinoma","Lung Neoplasms","Disease Management","Combined Modality Therapy","Clinical Decision-Making"],"mesh_terms":["Clinical Decision-Making","Combined Modality Therapy","Humans","Lung Neoplasms","Disease Management","Small Cell Lung Carcinoma"],"keywords":["Medicine","Systemic therapy","Context (archaeology)","Psychosocial","Radiation therapy","Lung cancer","Intensive care medicine","Immunotherapy","Disease","Oncology","Cancer","Internal medicine","Psychiatry"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-29T21:55:22.585437Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}